In summary, perhexiline inhibits fatty acid uptake by cardiomyocytes and may be promising for HF treatment, in addition to its known pharmacological effects, such as L-type calcium channel inhibition, inhibition of HERG and Kv1.5 potassium channels, potentiation of insulin release, and reductions in platelet reactivity mediated by cyclic guanosine monophosphate and nitric oxide [174]. The gene discussed is INS; the disease is hydrops fetalis.